Aktywności polskich naukowców podczas kongresu ESMO 19-23 października 2018 r.

24 października 2018

Aktywności polskich naukowców podczas kongresu ESMO, który odbył się w dniach 19-23 października 2018 r. w Monachium:

  • Rutkowski P., "Neo-adjuvant and adjuvant strategies in melanoma – Conclusions and clinical perspectives”.
  • Rutkowski P., "Pre-op/neoadjuvant treatment in sarcomas: 'Think before you open it' - The surgeon's perspective”.
  • Senkus-Konefka E., "Let's talk women's cancers - Additional perspective: Focus on Breast Cancer Patient Guide”.
  • Senkus-Konefka E., "ESMO Clinical Practice Guidelines 2” – discussant.
  • Dziadziuszko R., 1379PD - "Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study”.
  • Jurczak W., 1014PD - "Phase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies”.
  • Kosela-Paterczyk I., 1609PD - "Preoperative hypofractionated radiotherapy (RT) in patients with locally advanced myxoid liposarcomas: interim analysis of prospective phase II clinical trial”.
  • Czarnecka E. i wsp., 1263P - "The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice”.
  • Dubiański R. i wsp., 17P – "HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch”.
  • Huszno i wsp., 1871P - "Survival from breast cancer in patients with BRCA1/2, CHEK2, NOD2 mutations and TP53 (c.[215G>C]) polymorphisms”.
  • Idasiak A. i wsp., 495P - "Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: A phase III clinical study”.
  • Jagielska B. i wsp., 327P - "Survival of HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine – a national population-based study: long-term analysis”.
  • Jancewicz I. i wsp., 1898P - "The role of SWI/SNF chromatin remodelling complex ATPase subunit - BRM in TNBC”.
  • Krajewska i wsp., 1829TiP - "A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)”.
  • Lisowska K. i wsp., 38P – "Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro”.
  • Skupińska i wsp., 647P - "The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy”.
  • Spałek M. i wsp., 1628P - "Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: Interim analysis of prospective phase II clinical trial”.
  • Talasiewicz i wsp., 1723P - "Comparison of venous thromboembolism risk assessment models in patients receiving chemotherapy”.
  • Wasylecka- Juszczyńska M. i wsp., 1299P - "BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation”.
  • Zaucha R. i wsp., 1433P - "Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in advanced non-small cell lung cancer”.

212.114.167.162/slidecenter/esmo2018